Compare

Zymeworks Inc. vs Zevra Therapeutics, Inc. vs Siga Technologies Inc vs Standard Biotools Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearZymeworks Inc.
ZYME
Zevra Therapeutics, Inc.
ZVRA
Siga Technologies Inc
SIGA
Standard Biotools Inc.
LAB
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$105.97M$106.47M$94.57M$85.33M
Revenue growth (YoY)+38.9%+350.9%-31.8%-6.2%
Gross marginn/an/a68.6% (computed)49.9%
Operating margin-87.3%-59.1%25.1%-129.2%
Net margin-76.6%78.2%24.6%-87.8%
Net income-$81.13M$83.23M$23.28M-$74.90M
EPS (Diluted)-$1.08$1.35$0.32-$0.20
Operating cash flow-$33.01M-$1.60M$43.47M-$74.34M
Free cash flow-$34.53M-$2.43Mn/a-$82.65M
Cash & equivalents$41.16M$62.41M$154.97M$120.86M
Total assets$346.53M$284.73M$219.47M$567.75M
Total liabilities$78.03M$130.07M$20.65M$143.46M
Shareholders' equity$268.50M$154.66M$198.82M$424.29M
Return on year-end equity-30.2%53.8%11.7%-17.7%
Shares outstanding74.64M56.85M71.61M386.38M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearZymeworks Inc.Zevra Therapeutics, Inc.Siga Technologies IncStandard Biotools Inc.
Latest$105.97M
Ended 2025-12-31
$106.47M
Ended 2025-12-31
$94.57M
Ended 2025-12-31
$85.33M
Ended 2025-12-31
1 year earlier$76.30M
Ended 2024-12-31
$23.61M
Ended 2024-12-31
$138.72M
Ended 2024-12-31
$91.01M
Ended 2024-12-31
2 years earlier$76.01M
Ended 2023-12-31
$27.46M
Ended 2023-12-31
$139.92M
Ended 2023-12-31
$106.34M
Ended 2023-12-31
3 years earlier$412.48M
Ended 2022-12-31
$10.16M
Ended 2022-12-31
$110.78M
Ended 2022-12-31
$97.95M
Ended 2022-12-31
4 years earlier$26.68M
Ended 2021-12-31
$28.65M
Ended 2021-12-31
$133.67M
Ended 2021-12-31
$130.58M
Ended 2021-12-31